A Phase 3 interventional study of Levetiracetam in Epilepsy, Partial, sponsored by UCB Japan Co. Ltd.. Completed. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2019-06-10.
Sponsored by UCB Japan Co. Ltd. (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.
Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 10th largest by enrollment, is the only one that started in 2001, is one of 10 in phase 3, and was the 5th registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →
Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 16 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 173 across the 18 interventional studies. Of the 18 that completed or were terminated, 10 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 18 have an industry lead sponsor. The 8 most frequent:
This study is registered under UCB Japan Co. Ltd., one of the names counted as UCB S.A.. Under that name alone:
UCB Japan Co. Ltd. is the lead sponsor of 14 studies on the registry; none are open to participants now.
29 studies in Epilepsies, Partial by UCB S.A.: none open now, none under way, none of them phase 3. Of 27 finished, 18 (67%) have results posted.
Among the 29 studies in Epilepsies, Partial by UCB S.A., this one is the 13th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2001, is one of 11 in phase 3, and was the 8th registered.
UCB S.A.’s Epilepsies, Partial studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing levetiracetam in Epilepsies, Partial, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among UCB S.A.’s 29 in Epilepsies, Partial:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The safety and efficacy of L059 was evaluated in patients who completed "N165 Clinical Trial of L059". They received L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their standard concomitant AEDs
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects received oral tablets of Levetiracetam. This study N01020 (NCT00160615) was designed as a single group assignment study and as follow-up study, open for patients from N165 (NCT00600509). The differentiation into placebo and Levetiracetam in the results reporting section is based on the treatment of the previously conducted study N165 (NCT00600509).
Drug: Levetiracetam
* Pharmaceutical form: Film-coating tablets * Concentration: 250 mg/ 500 mg * Route of administration: oral use
Also known as: Keppra
Partial (Type I) Seizure Frequency Per Week by Analysis Visit
Number of Partial (Type I) seizures over the treatment period standardized to 1 week period.
Time frame: From Baseline up to 54 months
Partial (Type IA) Seizure Frequency Per Week by Analysis Visit
Number of Partial (Type IA) seizures over the treatment period standardized to 1 week period.
Time frame: From Baseline up to 54 months
Partial (Type IB) Seizure Frequency Per Week by Analysis Visit
Number of Partial (Type IB) seizures over the treatment period standardized to 1 week period.
Time frame: From Baseline up to 54 months
Partial (Type IC) Seizure Frequency Per Week by Analysis Visit
Number of Partial (Type IC) seizures over the treatment period standardized to 1 week period.
Time frame: From Baseline up to 54 months
Percentage Change From Baseline of Partial Onset Seizure Frequency (Type I Overall) Per Week by Analysis Visit
Percentage change from baseline of of Partial (Type I) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.
Time frame: From Baseline up to 54 months
Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IA) Per Week by Analysis Visit
Percentage change from baseline of of Partial (Type IA) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.
Time frame: From Baseline up to 54 months
Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IB) Per Week by Analysis Visit
Percentage change from baseline of of Partial (Type IB) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.
Time frame: From Baseline up to 54 months
Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IC) Per Week by Analysis Visit
Percentage change from baseline of of Partial (Type IC) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.
Time frame: From Baseline up to 54 months
The study started to enroll patients in September 2001 and concluded in January 2007.
| Milestone | N165 Randomized Treatment PBO | N165 Randomized Treatment LEV |
|---|---|---|
| Started | 50 | 101 |
| Completed | 32 | 56 |
| Not completed | 18 | 45 |
| Withdrew: Adverse event | 5 | 12 |
| Withdrew: Withdrawal by subject | 0 | 2 |
| Withdrew: Lack of efficacy | 11 | 23 |
| Withdrew: Patient decision | 1 | 2 |
| Withdrew: Investigator decision | 1 | 1 |
| Withdrew: Ae agents had to be discontinued (exam.) | 0 | 1 |
| Withdrew: Switch to surgical treatment | 0 | 2 |
| Withdrew: Non-compliance was suspected | 0 | 1 |
| Withdrew: Poor compliance | 0 | 1 |
Number of Partial (Type I) seizures over the treatment period standardized to 1 week period.
| Number of Seizures (Type I) per week | N165 Randomized Treatment PBO | N165 Randomized Treatment LEV |
|---|---|---|
| >= 1 day(d) - <= 3 months(m) | 1.68 (1.18 to 4.06) | 2.19 (0.99 to 5.41) |
| > 3 m - <= 6 m | 1.69 (1.00 to 2.75) | 2.00 (0.87 to 4.48) |
| > 6 m - <= 9 m | 1.58 (0.88 to 2.69) | 1.78 (0.68 to 4.94) |
| > 9 m - <= 12 m | 1.41 (0.95 to 3.25) | 1.60 (0.60 to 5.05) |
| > 12 m - <= 15 m | 1.58 (1.06 to 2.50) | 1.55 (0.80 to 4.67) |
| > 15 m - <= 18 m | 1.36 (1.03 to 2.32) | 1.69 (0.75 to 4.80) |
| > 18 m - <= 21 m | 1.35 (0.72 to 1.96) | 1.51 (0.62 to 4.49) |
| > 21 m - <= 24 m | 1.30 (0.75 to 1.98) | 1.36 (0.67 to 3.17) |
| > 24 m - <= 27 m | 1.25 (0.56 to 2.38) | 1.33 (0.82 to 2.80) |
| > 27 m - <= 30 m | 1.30 (0.66 to 2.46) | 1.28 (0.72 to 2.75) |
| > 30 m - <= 33 m | 1.21 (0.71 to 2.65) | 1.33 (0.77 to 2.83) |
| > 33 m - <= 36 m | 1.14 (0.68 to 2.69) | 1.30 (0.71 to 3.31) |
| > 36 m - <= 39 m | 1.20 (0.65 to 2.92) | 1.28 (0.75 to 3.32) |
| > 39 m - <= 42 m | 1.25 (0.50 to 2.91) | 1.32 (0.58 to 2.62) |
| > 42 m - <= 45 m | 1.17 (0.79 to 2.41) | 1.28 (0.60 to 2.49) |
| > 45 m - <= 48 m | 0.95 (0.54 to 2.05) | 1.09 (0.25 to 1.58) |
| > 48 m - <= 51 m | 0.90 (0.31 to 1.61) | 0.70 (0.14 to 1.42) |
| > 51 m - <= 54 m | 1.06 (0.08 to 2.17) | 0.78 (0.11 to 1.33) |
| > 54 m | 1.16 (0.27 to 1.65) | 0.09 (0.08 to 1.16) |
Number of Partial (Type IA) seizures over the treatment period standardized to 1 week period.
| Number of Seizures (Type IA) per week | N165 Randomized Treatment PBO | N165 Randomized Treatment LEV |
|---|---|---|
| >= 1 d - <= 3 m | 0.86 (0.07 to 1.73) | 0.68 (0.06 to 4.41) |
| > 3 m - <= 6 m | 0.32 (0.06 to 1.44) | 0.83 (0.06 to 3.31) |
| > 6 m - <= 9 m | 0.24 (0.00 to 1.33) | 0.63 (0.05 to 4.67) |
| > 9 m - <= 12 m | 0.26 (0.00 to 1.23) | 0.50 (0.00 to 3.47) |
| > 12 m - <= 15 m | 0.57 (0.09 to 1.35) | 0.22 (0.00 to 2.74) |
| > 15 m - <= 18 m | 0.27 (0.00 to 1.32) | 0.30 (0.00 to 2.81) |
| > 18 m - <= 21 m | 0.10 (0.00 to 1.38) | 0.42 (0.00 to 1.82) |
| > 21 m - <= 24 m | 0.17 (0.06 to 1.00) | 0.43 (0.05 to 1.60) |
| > 24 m - <= 27 m | 0.29 (0.00 to 1.10) | 0.25 (0.00 to 1.41) |
| > 27 m - <= 30 m | 0.44 (0.00 to 1.06) | 0.17 (0.00 to 1.41) |
| > 30 m - <= 33 m | 0.24 (0.00 to 0.98) | 0.25 (0.08 to 1.32) |
| > 33 m - <= 36 m | 0.17 (0.00 to 0.83) | 0.29 (0.05 to 1.63) |
| > 36 m - <= 39 m | 0.14 (0.00 to 0.40) | 0.13 (0.04 to 1.50) |
| > 39 m - <= 42 m | 0.17 (0.00 to 0.83) | 0.28 (0.04 to 1.29) |
| > 42 m - <= 45 m | 0.09 (0.00 to 1.13) | 0.44 (0.08 to 1.03) |
| > 45 m - <= 48 m | 0.20 (0.08 to 0.97) | 0.48 (0.09 to 1.38) |
| > 48 m - <= 51 m | 0.44 (0.00 to 1.42) | 0.18 (0.00 to 1.17) |
| > 51 m - <= 54 m | 0.62 (0.00 to 1.59) | 0.17 (0.10 to 0.63) |
| > 54 m | 0.87 (0.14 to 1.65) | 0.08 (0.00 to 0.84) |
Number of Partial (Type IB) seizures over the treatment period standardized to 1 week period.
| Number of Seizures (Type IB) per week | N165 Randomized Treatment PBO | N165 Randomized Treatment LEV |
|---|---|---|
| >= 1 d - <= 3 m | 1.56 (0.94 to 2.49) | 1.27 (0.50 to 3.25) |
| > 3 m - <= 6 m | 1.51 (0.81 to 2.69) | 1.13 (0.38 to 3.18) |
| > 6 m <= 9 m | 1.30 (0.60 to 2.25) | 0.92 (0.25 to 2.31) |
| > 9 m - <= 12 m | 1.39 (0.80 to 1.88) | 0.72 (0.24 to 2.11) |
| > 12 m - <= 15 m | 1.34 (0.71 to 1.94) | 0.81 (0.38 to 2.12) |
| > 15 m - <= 18 m | 1.25 (0.81 to 2.21) | 0.81 (0.35 to 1.88) |
| > 18 m - <= 21 m | 1.25 (0.72 to 1.95) | 0.58 (0.31 to 2.34) |
| > 21 m - <= 24 m | 1.26 (0.70 to 1.90) | 0.73 (0.26 to 2.65) |
| > 24 m - <= 27 m | 1.21 (0.56 to 2.50) | 0.85 (0.13 to 2.05) |
| > 27 m - <= 30 m | 1.21 (0.66 to 3.33) | 0.98 (0.15 to 1.74) |
| > 30 m - <= 33 m | 1.25 (0.69 to 2.84) | 0.79 (0.20 to 2.04) |
| > 33 m - <= 36 m | 1.15 (0.76 to 2.91) | 0.96 (0.14 to 2.13) |
| > 36 m - <= 39 m | 1.28 (0.80 to 3.43) | 1.04 (0.17 to 2.48) |
| > 39 m - <= 42 m | 1.40 (0.66 to 3.48) | 0.77 (0.13 to 1.71) |
| > 42 m - <= 45 m | 1.22 (0.76 to 2.79) | 0.89 (0.08 to 1.52) |
| > 45 m - <= 48 m | 0.87 (0.46 to 2.89) | 0.27 (0.00 to 1.36) |
| > 48 m - <= 51 m | 0.74 (0.33 to 2.46) | 0.22 (0.02 to 1.15) |
| > 51 m - <= 54 m | 0.80 (0.46 to 3.64) | 0.19 (0.00 to 1.25) |
| > 54 m | 0.72 (0.54 to 1.33) | 0.09 (0.00 to 0.17) |
Number of Partial (Type IC) seizures over the treatment period standardized to 1 week period.
| Number of Seizures (Type IC) per week | N165 Randomized Treatment PBO | N165 Randomized Treatment LEV |
|---|---|---|
| >= 1 d - <= 3 m | 0.00 (0.00 to 0.31) | 0.00 (0.00 to 0.19) |
| > 3 m - <= 6 m | 0.00 (0.00 to 0.13) | 0.00 (0.00 to 0.07) |
| > 6 m - <= 9 m | 0.05 (0.00 to 0.19) | 0.00 (0.00 to 0.13) |
| > 9 m - <= 12 m | 0.06 (0.00 to 0.17) | 0.00 (0.00 to 0.06) |
| > 12 m - <= 15 m | 0.06 (0.00 to 0.07) | 0.00 (0.00 to 0.03) |
| > 15 m - <= 18 m | 0.00 (0.00 to 0.13) | 0.00 (0.00 to 0.06) |
| > 18 m - <= 21 m | 0.00 (0.00 to 0.17) | 0.00 (0.00 to 0.00) |
| > 21 m - <= 24 m | 0.05 (0.00 to 0.14) | 0.00 (0.00 to 0.00) |
| > 24 m - <= 27 m | 0.02 (0.00 to 0.17) | 0.00 (0.00 to 0.00) |
| > 27 m - <= 30 m | 0.04 (0.00 to 0.13) | 0.00 (0.00 to 0.00) |
| > 30 m - <= 33 m | 0.09 (0.00 to 0.16) | 0.00 (0.00 to 0.00) |
| > 33 m - <= 36 m | 0.06 (0.00 to 0.13) | 0.00 (0.00 to 0.00) |
| > 36 m - <= 39 m | 0.04 (0.00 to 0.08) | 0.00 (0.00 to 0.00) |
| > 39 m - <= 42 m | 0.08 (0.00 to 0.08) | 0.00 (0.00 to 0.00) |
| > 42 m - <= 45 m | 0.04 (0.00 to 0.19) | 0.00 (0.00 to 0.02) |
| > 45 m - <= 48 m | 0.02 (0.00 to 0.04) | 0.00 (0.00 to 0.00) |
| > 48 m - <= 51 m | 0.00 (0.00 to 0.04) | 0.00 (0.00 to 0.00) |
| > 51 m - <= 54 m | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
| > 54 m | 0.00 (0.00 to 0.00) | 0.00 (0.00 to 0.00) |
Percentage change from baseline of of Partial (Type I) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.
| Percent change | N165 Randomized Treatment PBO | N165 Randomized Treatment LEV |
|---|---|---|
| >= 1 d - <= 3 m | -27.39 (-48.11 to 5.37) | -31.24 (-61.33 to 2.86) |
| > 3 m - <= 6 m | -35.15 (-58.61 to -6.20) | -34.74 (-62.48 to -3.22) |
| > 6 m - <= 9 m | -38.42 (-59.44 to 5.08) | -43.03 (-77.38 to -9.61) |
| > 9 m - <= 12 m | -41.44 (-61.30 to -6.63) | -43.11 (-73.76 to -11.60) |
| > 12 m - <= 15 m | -29.58 (-58.69 to -10.04) | -46.38 (-73.80 to -11.12) |
| > 15 m - <= 18 m | -44.44 (-70.68 to -19.37) | -43.17 (-69.33 to -16.84) |
| > 18 m - <= 21 m | -37.58 (-69.96 to -21.23) | -49.61 (-71.95 to -20.04) |
| > 21 m - <= 24 m | -45.75 (-59.76 to -15.74) | -52.96 (-77.16 to -13.78) |
| > 24 m - <= 27 m | -50.89 (-69.36 to 0.01) | -53.78 (-73.22 to -23.05) |
| > 27 m - <= 30 m | -40.54 (-74.09 to -1.74) | -47.71 (-76.29 to -18.07) |
| > 30 m - <= 33 m | -29.96 (-69.05 to 0.00) | -43.09 (-76.80 to -16.09) |
| > 33 m - <= 36 m | -40.03 (-72.14 to -5.33) | -39.01 (-75.01 to -11.31) |
| > 36 m - <= 39 m | -43.67 (-68.70 to 3.89) | -44.42 (-74.06 to -9.63) |
| > 39 m - <= 42 m | -42.88 (-65.68 to 0.20) | -47.69 (-85.88 to -10.34) |
| > 42 m - <= 45 m | -45.06 (-57.76 to -21.01) | -71.96 (-85.97 to -21.29) |
| > 45 m - <= 48 m | -42.41 (-71.81 to -28.73) | -80.02 (-86.42 to -36.37) |
| > 48 m - <= 51 m | -49.11 (-74.26 to -23.92) | -78.28 (-88.06 to -55.91) |
| > 51 m - <= 54 m | -43.74 (-96.55 to 0.60) | -81.81 (-92.97 to -66.12) |
| > 54 m | -40.72 (-76.94 to -14.12) | -90.00 (-92.17 to -85.37) |
Percentage change from baseline of of Partial (Type IA) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.
| Percent change | N165 Randomized Treatment PBO (FAS) | N165 Randomized Treatment LEV (FAS) |
|---|---|---|
| >= 1 d - <= 3 m | -79.58 (-89.22 to -24.55) | -45.93 (-88.28 to 14.97) |
| > 3 m - <= 6 m | -77.15 (-95.81 to -43.42) | -58.81 (-83.66 to 9.91) |
| > 6 m - <= 9 m | -71.71 (-100.00 to -39.06) | -61.62 (-86.96 to 45.98) |
| > 9 m - <= 12 m | -66.05 (-100.00 to -42.98) | -69.01 (-99.09 to -24.55) |
| > 12 m - <= 15 m | -37.32 (-96.72 to -19.64) | -78.44 (-100.00 to -43.42) |
| > 15 m - <= 18 m | -79.55 (-100.00 to -46.11) | -71.42 (-93.19 to -9.46) |
| > 18 m - <= 21 m | -83.68 (-100.00 to -39.59) | -66.07 (-97.31 to -19.52) |
| > 21 m - <= 24 m | -82.30 (-99.71 to -50.87) | -73.18 (-87.28 to -7.74) |
| > 24 m - <= 27 m | -72.52 (-99.68 to -49.91) | -74.85 (-91.27 to -33.43) |
| > 27 m - <= 30 m | -74.89 (-98.71 to -46.15) | -76.45 (-95.81 to -12.09) |
| > 30 m - <= 33 m | -80.89 (-98.97 to -48.35) | -78.24 (-89.74 to -4.31) |
| > 33 m - <= 36 m | -84.13 (-100.00 to -48.15) | -80.40 (-96.99 to 9.85) |
| > 36 m - <= 39 m | -90.62 (-100.00 to -53.87) | -76.79 (-97.71 to -27.78) |
| > 39 m - <= 42 m | -92.50 (-100.00 to -42.88) | -75.66 (-96.10 to -18.07) |
| > 42 m - <= 45 m | -77.00 (-99.57 to -47.52) | -74.09 (-93.06 to -39.64) |
| > 45 m - <= 48 m | -71.43 (-91.25 to -47.31) | -79.25 (-95.95 to -41.45) |
| > 48 m - <= 51 m | -54.01 (-95.64 to -48.88) | -91.41 (-100.00 to -56.26) |
| > 51 m - <= 54 m | -64.18 (-100.00 to -42.73) | -83.37 (-98.18 to -71.43) |
| > 54 m | -59.19 (-92.21 to -32.87) | -97.55 (-100.00 to -85.71) |
Percentage change from baseline of of Partial (Type IB) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.
| Percent change | N165 Randomized Treatment PBO (FAS) | N165 Randomized Treatment LEV (FAS) |
|---|---|---|
| >= 1 d - <= 3 m | -21.41 (-48.68 to 19.61) | -26.77 (-57.30 to 6.25) |
| > 3 m - <= 6 m | -21.95 (-52.22 to 2.27) | -31.35 (-64.47 to 0.53) |
| > 6 m - <= 9 m | -28.30 (-52.22 to 7.30) | -47.61 (-75.99 to -7.14) |
| > 9 m - <= 12 m | -34.97 (-50.02 to 17.70) | -43.56 (-73.35 to -14.31) |
| > 12 m - <= 15 m | -21.12 (-54.73 to 7.78) | -51.20 (-74.85 to 6.18) |
| > 15 m - <= 18 m | -33.18 (-56.67 to 6.88) | -45.80 (-66.80 to -12.59) |
| > 18 m - <= 21 m | -32.78 (-54.73 to 2.63) | -52.04 (-72.79 to -15.92) |
| > 21 m - <= 24 m | -20.12 (-58.09 to 1.17) | -52.96 (-78.82 to -10.93) |
| > 24 m - <= 27 m | -28.75 (-61.84 to 13.15) | -49.71 (-72.31 to -17.12) |
| > 27 m - <= 30 m | -8.84 (-51.80 to 3.05) | -48.18 (-79.29 to -21.93) |
| > 30 m - <= 33 m | -15.85 (-52.14 to 16.16) | -46.86 (-79.88 to -11.48) |
| > 33 m - <= 36 m | -11.73 (-53.45 to 17.68) | -42.03 (-74.93 to -6.07) |
| > 36 m - <= 39 m | -15.06 (-49.40 to 28.76) | -46.25 (-76.15 to 7.85) |
| > 39 m - <= 42 m | -20.13 (-53.31 to 31.25) | -49.85 (-86.73 to 0.00) |
| > 42 m - <= 45 m | -23.76 (-46.47 to 13.76) | -46.51 (-91.95 to -11.07) |
| > 45 m - <= 48 m | -37.52 (-56.10 to -13.36) | -54.05 (-98.11 to -16.56) |
| > 48 m - <= 51 m | -42.17 (-53.57 to 1.70) | -77.08 (-94.99 to -38.37) |
| > 51 m - <= 54 m | 5.38 (-44.75 to 10.33) | -74.58 (-100.00 to 42.13) |
| > 54 m | 3.55 (-47.49 to 74.45) | -86.61 (-93.85 to -8.06) |
Percentage change from baseline of of Partial (Type IC) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline.
| Percent change | N165 Randomized Treatment PBO | N165 Randomized Treatment LEV |
|---|---|---|
| >= 1 d - <= 3 m | -100.00 (-100.00 to -24.55) | -100.00 (-100.00 to -32.50) |
| > 3 m - <= 6 m | -93.96 (-100.00 to -59.36) | -100.00 (-100.00 to -32.10) |
| > 6 m - <= 9 m | -88.73 (-100.00 to 38.32) | -100.00 (-100.00 to -43.42) |
| > 9 m - <= 12 m | -100.00 (-100.00 to -54.73) | -100.00 (-100.00 to -40.03) |
| > 12 m - <= 15 m | -88.33 (-100.00 to -49.70) | -100.00 (-100.00 to -64.50) |
| > 15 m - <= 18 m | -100.00 (-100.00 to -62.28) | -100.00 (-100.00 to -69.82) |
| > 18 m - <= 21 m | -90.42 (-100.00 to -54.73) | -100.00 (-100.00 to -25.61) |
| > 21 m - <= 24 m | -80.56 (-100.00 to -24.55) | -100.00 (-100.00 to -68.35) |
| > 24 m - <= 27 m | -91.92 (-100.00 to -24.55) | -100.00 (-100.00 to -45.54) |
| > 27 m - <= 30 m | -92.11 (-100.00 to -74.85) | -100.00 (-100.00 to -45.54) |
| > 30 m - <= 33 m | -77.02 (-95.91 to 16.78) | -100.00 (-100.00 to -86.64) |
| > 33 m - <= 36 m | -74.30 (-91.72 to -46.59) | -100.00 (-100.00 to -92.19) |
| > 36 m - <= 39 m | -85.67 (-96.25 to -7.06) | -100.00 (-100.00 to -83.77) |
| > 39 m - <= 42 m | -83.23 (-100.00 to -21.27) | -100.00 (-100.00 to -47.52) |
| > 42 m - <= 45 m | -79.75 (-100.00 to -56.26) | -100.00 (-100.00 to -49.70) |
| > 45 m - <= 48 m | -95.81 (-100.00 to -83.23) | -100.00 (-100.00 to -85.94) |
| > 48 m - <= 51 m | -95.98 (-100.00 to -87.62) | -100.00 (-100.00 to -100.00) |
| > 51 m - <= 54 m | -100.00 (-100.00 to -91.67) | -100.00 (-100.00 to -100.00) |
| > 54 m | -100.00 (-100.00 to -100.00) | -100.00 (-100.00 to -100.00) |
Collected over Adverse events were collected from Visit 1 (Week 0) until 2 weeks after termination (up to 54 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| N165 Randomized Treatment PBO (FAS) | 0/50 (0%) | 12/50 (24%) | 48/50 (96%) |
| N165 Randomized Treatment LEV (FAS) | 1/101 (1%) | 22/101 (21.8%) | 99/101 (98%) |
| Event | N165 Randomized Treatment PBO (FAS) | N165 Randomized Treatment LEV (FAS) |
|---|---|---|
| ConvulsionNervous system disorders | 1/50 | 5/101 |
| Status epilepticusNervous system disorders | 2/50 | 4/101 |
| PneumoniaInfections and infestations | 0/50 | 3/101 |
| Abdominal pain lowerGastrointestinal disorders | 1/50 | 0/101 |
| Difficulty in walkingGeneral disorders | 1/50 | 0/101 |
| Gallbladder polypHepatobiliary disorders | 1/50 | 0/101 |
| AppendicitisInfections and infestations | 1/50 | 0/101 |
| ContusionInjury, poisoning and procedural complications | 1/50 | 0/101 |
| FallInjury, poisoning and procedural complications | 1/50 | 1/101 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/50 | 0/101 |
| Event | N165 Randomized Treatment PBO (FAS) | N165 Randomized Treatment LEV (FAS) |
|---|---|---|
| NasopharyngitisInfections and infestations | 38/50 | 76/101 |
| ConvulsionNervous system disorders | 2/5 | 9/101 |
| ContusionInjury, poisoning and procedural complications | 16/50 | 29/101 |
| HeadacheNervous system disorders | 16/50 | 28/101 |
| DiarrhoeaGastrointestinal disorders | 5/50 | 27/101 |
| SomnolenceNervous system disorders | 13/50 | 25/101 |
| DizzinessNervous system disorders | 12/50 | 20/101 |
| Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders | 12/50 | 22/101 |
| ConstipationGastrointestinal disorders | 4/50 | 20/101 |
| PyrexiaGeneral disorders | 9/50 | 14/101 |
Full analysis Set (FAS)
| Age, Continuous(Years) | N165 Randomized Treatment PBO (FAS) | N165 Randomized Treatment LEV (FAS) | Total Title |
|---|---|---|---|
| Mean | 33.19 ± 9.99 | 31.95 ± 10.19 | 32.36 ± 10.11 |
| Age, Customized(Participants) | N165 Randomized Treatment PBO (FAS) | N165 Randomized Treatment LEV (FAS) | Total Title |
|---|---|---|---|
| <=18 years | 2 | 6 | 8 |
| Between 18 and 65 years | 48 | 95 | 143 |
| Sex: Female, Male(Participants) | N165 Randomized Treatment PBO (FAS) | N165 Randomized Treatment LEV (FAS) | Total Title |
|---|---|---|---|
| Female | 27 | 47 | 74 |
| Male | 23 | 54 | 77 |
No study locations are listed for this record.
Ran from Sep 2001 to primary completion in Jan 2007, 64 months.
Results were first posted in Jun 2019, 12 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam